Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042679 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00042679: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00042679 is a Phase 2 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042679, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine. Whether LY900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.
Interventions
- DRUG Carboplatin
- DRUG Gemcitabine
- DRUG LY900003
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-06 |
| Phase | Phase 2 |
What the finished NCT00042679 record still lists
NCT00042679 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00042679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00042679 about?
NCT00042679 is a clinical study titled "A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.". The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine an...
What is the current status of trial NCT00042679?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-06.
What interventions are being tested in trial NCT00042679?
The interventions under investigation include: Carboplatin (DRUG), Gemcitabine (DRUG), LY900003 (DRUG).
Who is sponsoring clinical trial NCT00042679?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia